An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
A potential breakthrough in cardiovascular medicine has emerged with the development of lepodisiran, an experimental drug by pharmaceutical company Eli Lilly.The drug has demonstrated an unpreceden…